ArticleWomen's health (London, England)
Longitudinal Australian trends in the initiation of valproate medication among women of reproductive age and concurrent use of prescription contraceptives.
Article in Women's health (London, England). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAwareness of the risks of prescribing valproate to girls and women of childbearing potential has increased, with some countries strongly restricting prescribing and requiring pregnancy prevention plans.
objectivesTo explore changes in valproate dispensing patterns and the proportion of women covered by prescription contraceptives, especially long-acting forms, in Australia.
designPopulation-based cohort study using routinely collected government data on dispensed medications.
methodsWe analysed a 10% random sample of Australian Pharmaceutical Benefits Scheme (PBS) dispensing data for women aged 15-49 years. We calculated the annual rate of initiating valproate and alternative anti-seizure medications. We assessed what proportion of women were covered by long-acting or other PBS prescription contraception at treatment commencement.
resultsBetween 2013 and 2021, overall valproate initiation declined substantially (from 2.06 to 0.75 per 1000 women per annum), compensated by a rise in the initiation of alternative anti-seizure medications. This reflected a decline in valproate initiated as a first-line treatment, with valproate initiated as a second-line treatment remaining stable. For women initiating valproate, contraception coverage by an intrauterine device or implant increased from 16% in 2013 to 22% in 2021. In 2021, no coverage by PBS prescription contraceptives occurred in 69% of women initiating valproate and 68% of women initiating alternative anti-seizure medications.
conclusionsA decline in valproate prescribing has occurred in Australia. At the time treatment commenced, the great majority of women dispensed valproate were not covered by any form of PBS prescription contraceptive, which is of concern.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.